Related Experiment Videos
The Open Insulin Project: A Case Study for 'Biohacked' Medicines
Jenna E Gallegos1, Christopher Boyer2, Eleanore Pauwels3
1Department of Chemical and Biological Engineering, Colorado State University, Fort Collins, CO, USA.
Trends in Biotechnology
|September 18, 2018
Summary
The Open Insulin Project aims to lower drug costs by creating open-source insulin production. Regulatory hurdles, not patents, are the key challenge to affordable insulin in the US.
Area of Science:
- Pharmaceutical innovation
- Biotechnology
- Drug manufacturing
Background:
- Emerging innovation ecosystems challenge traditional drug development.
- The Open Insulin Project seeks to bypass patents for cheaper insulin production.
- US regulatory policies significantly impact pharmaceutical affordability.
Purpose of the Study:
- To analyze the Open Insulin Project's potential impact on insulin accessibility.
- To identify regulatory barriers to affordable drug manufacturing.
- To explore future scenarios of patient-driven pharmaceutical production.
Main Methods:
- Analysis of the Open Insulin Project's goals and strategies.
- Examination of the US intellectual property and regulatory landscape.
- Forecasting potential outcomes of open-source drug manufacturing protocols.
Main Results:
- The US regulatory environment presents a greater obstacle to insulin affordability than patent exclusivity.
- Successful implementation of an open insulin protocol could foster new production ecosystems.
- Patient empowerment in drug production is a potential future outcome.
Conclusions:
- Regulatory reform is crucial for improving insulin affordability.
- Open-source initiatives may offer alternative pathways for drug manufacturing.
- Future regulatory frameworks must adapt to evolving pharmaceutical production models, including patient self-production.